Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Tokyo VD who wrote (5839)	10/7/1998 11:57:00 AM
From: Linda Kaplan	Read Replies (2) \| Respond to of 7041

Tokyo: Is that likely to be a yearly estimate, a first year estimate, a lifetime estimate? Thanks for any elucidation. Linda

To: Tokyo VD who wrote (5839)	10/7/1998 11:58:00 AM
From: Ron Sigourney	Respond to of 7041

Toyko, Thanks. This is interesting, although remember this discussion is hypothetical. Thanks again. Ron

To: Tokyo VD who wrote (5839)	10/7/1998 12:14:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Ron & Tokyo, That's the only number I've seen - but only on this thread. Assuming it's correct, and let's say it's worldwide, here's one way of looking at it. From Zona's latest 10Q (with rounding), Product sales $ 4M Royalties $44 Total Rev. $48 CGS & Expenses $30 (22 is R&D) Profit $18 M EPS $1.50 x20 Multiple $30/share My .02 is that this is conservative - 20 is too low for the multiple -other products in development could easily make it 40 instead of 20 - all this IMHO - just one way to look at it. An aside, interesting that there was no doubt expressed about FDA approval.